Filing Details

Accession Number:
0001209191-23-045479
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-08-11 17:28:57
Reporting Period:
2023-08-09
Accepted Time:
2023-08-11 17:28:57
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1178879 Amicus Therapeutics Inc. FOLD Pharmaceutical Preparations (2834) 200422823
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1743122 Samantha Prout C/O Amicus Therapeutics, Inc.
3675 Market Street
Philadelphia PA 19104
Chief Accounting Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-08-09 2,376 $10.04 139,379 No 4 M Direct
Common Stock Acquisiton 2023-08-09 5,040 $9.55 144,419 No 4 M Direct
Common Stock Acquisiton 2023-08-09 10,592 $10.03 155,011 No 4 M Direct
Common Stock Acquisiton 2023-08-09 18,901 $12.11 173,912 No 4 M Direct
Common Stock Disposition 2023-08-09 36,909 $14.01 137,003 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (right to buy) Disposition 2023-08-09 2,376 $0.00 2,376 $10.04
Common Stock Stock Options (right to buy) Disposition 2023-08-09 5,040 $0.00 5,040 $9.55
Common Stock Stock Options (right to buy) Disposition 2023-08-09 10,592 $0.00 10,592 $10.03
Common Stock Stock Options (right to buy) Disposition 2023-08-09 18,901 $0.00 18,901 $12.11
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2029-01-02 No 4 M Direct
2,526 2030-01-02 No 4 M Direct
3,176 2030-04-15 No 4 M Direct
37,810 2032-01-14 No 4 M Direct
Footnotes
  1. This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.00 to $14.10 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. All of these options were fully vested and exercisable as of the transaction date.
  3. As of August 9, 2023, 5,985 options were fully vested and exercisable and 1,581 remained unvested from this individual 2020 grant.
  4. As of August 9, 2023, 11,164 options were fully vested and exercisable and 2,604 remained unvested from this individual 2020 grant.
  5. As of August 9, 2023, 22,444 options were fully vested and exercisable and 34,267 remained unvested from this individual 2022 grant.